JP2017533706A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533706A5 JP2017533706A5 JP2017523266A JP2017523266A JP2017533706A5 JP 2017533706 A5 JP2017533706 A5 JP 2017533706A5 JP 2017523266 A JP2017523266 A JP 2017523266A JP 2017523266 A JP2017523266 A JP 2017523266A JP 2017533706 A5 JP2017533706 A5 JP 2017533706A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- modified
- tcr
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 255
- 238000000034 method Methods 0.000 claims description 143
- 239000000427 antigen Substances 0.000 claims description 117
- 102000036639 antigens Human genes 0.000 claims description 117
- 108091007433 antigens Proteins 0.000 claims description 117
- 210000004027 cell Anatomy 0.000 claims description 94
- 108091008874 T cell receptors Proteins 0.000 claims description 83
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 83
- 102000039446 nucleic acids Human genes 0.000 claims description 71
- 108020004707 nucleic acids Proteins 0.000 claims description 71
- 150000007523 nucleic acids Chemical class 0.000 claims description 71
- 230000000139 costimulatory effect Effects 0.000 claims description 34
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 30
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 30
- 239000012634 fragment Substances 0.000 claims description 29
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 28
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 201000010099 disease Diseases 0.000 claims description 25
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 18
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 18
- 208000023275 Autoimmune disease Diseases 0.000 claims description 17
- 230000028993 immune response Effects 0.000 claims description 16
- 102000018697 Membrane Proteins Human genes 0.000 claims description 15
- 108010052285 Membrane Proteins Proteins 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 230000003834 intracellular effect Effects 0.000 claims description 15
- 208000030507 AIDS Diseases 0.000 claims description 14
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims description 14
- 208000001640 Fibromyalgia Diseases 0.000 claims description 14
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 14
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 14
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 14
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 14
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 14
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 14
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 14
- 208000011580 syndromic disease Diseases 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 13
- 201000001981 dermatomyositis Diseases 0.000 claims description 13
- 230000011664 signaling Effects 0.000 claims description 13
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 12
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 12
- 238000012258 culturing Methods 0.000 claims description 12
- 206010043207 temporal arteritis Diseases 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 9
- 102100027207 CD27 antigen Human genes 0.000 claims description 8
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 8
- 208000034189 Sclerosis Diseases 0.000 claims description 8
- 238000004520 electroporation Methods 0.000 claims description 8
- 208000008190 Agammaglobulinemia Diseases 0.000 claims description 7
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 7
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 7
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 7
- 208000023328 Basedow disease Diseases 0.000 claims description 7
- 208000009137 Behcet syndrome Diseases 0.000 claims description 7
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 7
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 102100035793 CD83 antigen Human genes 0.000 claims description 7
- 201000002829 CREST Syndrome Diseases 0.000 claims description 7
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 7
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 7
- 208000015943 Coeliac disease Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000011231 Crohn disease Diseases 0.000 claims description 7
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 7
- 208000015023 Graves' disease Diseases 0.000 claims description 7
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 7
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 7
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 7
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims description 7
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 7
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 7
- 206010021263 IgA nephropathy Diseases 0.000 claims description 7
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 206010025323 Lymphomas Diseases 0.000 claims description 7
- 208000027530 Meniere disease Diseases 0.000 claims description 7
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 7
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 7
- 206010065159 Polychondritis Diseases 0.000 claims description 7
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 7
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 7
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 7
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 7
- 208000033464 Reiter syndrome Diseases 0.000 claims description 7
- 206010038389 Renal cancer Diseases 0.000 claims description 7
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 7
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 7
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims description 7
- 208000001106 Takayasu Arteritis Diseases 0.000 claims description 7
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 7
- 206010047642 Vitiligo Diseases 0.000 claims description 7
- 208000004631 alopecia areata Diseases 0.000 claims description 7
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 7
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 201000010881 cervical cancer Diseases 0.000 claims description 7
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 7
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 210000003027 ear inner Anatomy 0.000 claims description 7
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 7
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 7
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 7
- 201000010982 kidney cancer Diseases 0.000 claims description 7
- 208000032839 leukemia Diseases 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 206010025135 lupus erythematosus Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 206010028417 myasthenia gravis Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 230000003071 parasitic effect Effects 0.000 claims description 7
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 7
- 208000005987 polymyositis Diseases 0.000 claims description 7
- 208000002574 reactive arthritis Diseases 0.000 claims description 7
- 201000003068 rheumatic fever Diseases 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 201000000306 sarcoidosis Diseases 0.000 claims description 7
- 201000000849 skin cancer Diseases 0.000 claims description 7
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 7
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 7
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 6
- 102000002627 4-1BB Ligand Human genes 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims description 6
- 108010002352 Interleukin-1 Proteins 0.000 claims description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims description 6
- 108010002386 Interleukin-3 Proteins 0.000 claims description 6
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims description 6
- 206010039710 Scleroderma Diseases 0.000 claims description 6
- 102000015215 Stem Cell Factor Human genes 0.000 claims description 6
- 108010039445 Stem Cell Factor Proteins 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 210000004700 fetal blood Anatomy 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 6
- 230000037390 scarring Effects 0.000 claims description 6
- 238000010257 thawing Methods 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- 238000010361 transduction Methods 0.000 claims description 5
- 230000026683 transduction Effects 0.000 claims description 5
- 238000001890 transfection Methods 0.000 claims description 5
- 206010034277 Pemphigoid Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 201000003278 cryoglobulinemia Diseases 0.000 claims description 3
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims description 2
- 206010003230 arteritis Diseases 0.000 claims description 2
- 201000002481 Myositis Diseases 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000011259 co-electroporation Methods 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 230000027455 binding Effects 0.000 description 33
- 150000003384 small molecules Chemical class 0.000 description 16
- 108700010039 chimeric receptor Proteins 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 11
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 10
- 230000009089 cytolysis Effects 0.000 description 10
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 8
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 7
- 208000026872 Addison Disease Diseases 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 6
- 208000012528 Juvenile dermatomyositis Diseases 0.000 description 6
- 201000010415 childhood type dermatomyositis Diseases 0.000 description 6
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 230000021633 leukocyte mediated immunity Effects 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 6
- -1 CD86 Proteins 0.000 description 5
- 208000011038 Cold agglutinin disease Diseases 0.000 description 5
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 5
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 5
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 5
- 230000005784 autoimmunity Effects 0.000 description 5
- 238000009172 cell transfer therapy Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 108010032795 CD8 receptor Proteins 0.000 description 4
- 108010091326 Cryoglobulins Proteins 0.000 description 4
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 4
- 201000009906 Meningitis Diseases 0.000 description 4
- 241000721454 Pemphigus Species 0.000 description 4
- 241000219095 Vitis Species 0.000 description 4
- 235000009754 Vitis X bourquina Nutrition 0.000 description 4
- 235000012333 Vitis X labruscana Nutrition 0.000 description 4
- 235000014787 Vitis vinifera Nutrition 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000001627 detrimental effect Effects 0.000 description 4
- 108010041397 CD4 Antigens Proteins 0.000 description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 102100026882 Alpha-synuclein Human genes 0.000 description 2
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 2
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 102100022339 Integrin alpha-L Human genes 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021084334A JP2021121208A (ja) | 2014-10-31 | 2021-05-19 | 改変ｔ細胞に関する方法および組成物 |
| JP2023088510A JP7757343B2 (ja) | 2014-10-31 | 2023-05-30 | 改変ｔ細胞に関する方法および組成物 |
| JP2025169833A JP2025188145A (ja) | 2014-10-31 | 2025-10-08 | 改変ｔ細胞に関する方法および組成物 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462073144P | 2014-10-31 | 2014-10-31 | |
| US201462073343P | 2014-10-31 | 2014-10-31 | |
| US201462073467P | 2014-10-31 | 2014-10-31 | |
| US201462073681P | 2014-10-31 | 2014-10-31 | |
| US201462073540P | 2014-10-31 | 2014-10-31 | |
| US62/073,467 | 2014-10-31 | ||
| US62/073,540 | 2014-10-31 | ||
| US62/073,343 | 2014-10-31 | ||
| US62/073,681 | 2014-10-31 | ||
| US62/073,144 | 2014-10-31 | ||
| PCT/US2015/058339 WO2016070061A1 (en) | 2014-10-31 | 2015-10-30 | Methods and compositions for modified t cells |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021084334A Division JP2021121208A (ja) | 2014-10-31 | 2021-05-19 | 改変ｔ細胞に関する方法および組成物 |
| JP2023088510A Division JP7757343B2 (ja) | 2014-10-31 | 2023-05-30 | 改変ｔ細胞に関する方法および組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2017533706A JP2017533706A (ja) | 2017-11-16 |
| JP2017533706A5 true JP2017533706A5 (show.php) | 2018-12-06 |
| JPWO2016070061A5 JPWO2016070061A5 (show.php) | 2023-06-08 |
| JP7372728B2 JP7372728B2 (ja) | 2023-11-01 |
Family
ID=55858404
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523266A Active JP7372728B2 (ja) | 2014-10-31 | 2015-10-30 | 改変ｔ細胞に関する方法および組成物 |
| JP2021084334A Withdrawn JP2021121208A (ja) | 2014-10-31 | 2021-05-19 | 改変ｔ細胞に関する方法および組成物 |
| JP2023088510A Active JP7757343B2 (ja) | 2014-10-31 | 2023-05-30 | 改変ｔ細胞に関する方法および組成物 |
| JP2025169833A Pending JP2025188145A (ja) | 2014-10-31 | 2025-10-08 | 改変ｔ細胞に関する方法および組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021084334A Withdrawn JP2021121208A (ja) | 2014-10-31 | 2021-05-19 | 改変ｔ細胞に関する方法および組成物 |
| JP2023088510A Active JP7757343B2 (ja) | 2014-10-31 | 2023-05-30 | 改変ｔ細胞に関する方法および組成物 |
| JP2025169833A Pending JP2025188145A (ja) | 2014-10-31 | 2025-10-08 | 改変ｔ細胞に関する方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20170258835A1 (show.php) |
| EP (2) | EP3212225B1 (show.php) |
| JP (4) | JP7372728B2 (show.php) |
| KR (1) | KR20170074243A (show.php) |
| CN (1) | CN107106670A (show.php) |
| AU (1) | AU2015338984A1 (show.php) |
| CA (1) | CA2964958A1 (show.php) |
| HK (1) | HK1243333A1 (show.php) |
| WO (1) | WO2016070061A1 (show.php) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3298033T4 (da) † | 2015-05-18 | 2023-10-02 | Tcr2 Therapeutics Inc | Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner |
| US11059880B2 (en) | 2015-06-30 | 2021-07-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Redirected cells with MHC chimeric receptors and methods of use in immunotherapy |
| US11649435B2 (en) | 2015-08-28 | 2023-05-16 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| CN108135932A (zh) * | 2015-08-28 | 2018-06-08 | 宾夕法尼亚大学董事会 | 表达嵌合细胞内信号传导分子的细胞的方法和组合物 |
| WO2017053889A2 (en) | 2015-09-23 | 2017-03-30 | Precision Immunotherapy, Inc. | Flt3 directed car cells for immunotherapy |
| WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
| US11001622B2 (en) | 2015-11-19 | 2021-05-11 | The Brigham And Women's Hospital, Inc. | Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein |
| EP3387114A1 (en) * | 2015-12-09 | 2018-10-17 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of using same |
| JP2019509753A (ja) * | 2016-03-31 | 2019-04-11 | ライオン ティーシーアール ピーティーイー．エルティーディー． | 外因性ウイルス特異的ｔ細胞受容体（ｔｃｒ）を発現する非活性化ｔ細胞 |
| KR20180135460A (ko) * | 2016-04-15 | 2018-12-20 | 자임워크스 인코포레이티드 | 면역치료제를 표적으로 하는 다중-특이적 항원-결합 작제물 |
| CN107522786A (zh) * | 2016-06-20 | 2017-12-29 | 深圳市体内生物医药科技有限公司 | 一种分子、表达其的细胞及其制备方法和用途 |
| CN107586342A (zh) * | 2016-07-08 | 2018-01-16 | 生命序有限公司 | 重组免疫检查点受体及其应用 |
| CN107586341A (zh) * | 2016-07-08 | 2018-01-16 | 生命序有限公司 | 重组免疫检查点受体及免疫检查点抑制分子的共表达及应用 |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| CN109863242A (zh) | 2016-08-30 | 2019-06-07 | 纪念斯隆-凯特林癌症中心 | 用于治疗病毒感染和其它感染的免疫细胞组合物和使用方法 |
| US20190262399A1 (en) | 2016-09-07 | 2019-08-29 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses |
| BR112019007100A2 (pt) | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão |
| WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| US12227578B2 (en) | 2016-11-11 | 2025-02-18 | The Broad Institute, Inc. | Modulation of intestinal epithelial cell differentiation, maintenance and/or function through T cell action |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| CN108264562B (zh) * | 2016-12-30 | 2021-08-10 | 惠和生物技术(上海)有限公司 | 一种结合cd3和t细胞正共刺激分子的双功能分子及其应用 |
| EP3575319A4 (en) | 2016-12-30 | 2021-03-10 | Shanghai Sinobio Biotech Co., Ltd. | BIFUNCTIONAL MOLECULE AND USE OF IT |
| WO2018132427A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Targeted t cells with cytotoxicity toward immunosuppressive cells |
| US11963966B2 (en) | 2017-03-31 | 2024-04-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
| WO2018183921A1 (en) | 2017-04-01 | 2018-10-04 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
| US20200071773A1 (en) | 2017-04-12 | 2020-03-05 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
| JP7505885B2 (ja) * | 2017-04-14 | 2024-06-25 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 |
| CN110868853A (zh) * | 2017-04-26 | 2020-03-06 | 纪念斯隆-凯特琳癌症中心 | 即用型冷冻保存细胞 |
| EP3622092A4 (en) | 2017-05-11 | 2021-06-23 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF |
| KR102379189B1 (ko) | 2017-06-13 | 2022-03-25 | 엘지디스플레이 주식회사 | 연성 표시 패널을 포함하는 롤러블 디스플레이 장치 |
| US11897953B2 (en) | 2017-06-14 | 2024-02-13 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| WO2019014581A1 (en) | 2017-07-14 | 2019-01-17 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE |
| KR20250006980A (ko) * | 2017-09-15 | 2025-01-13 | 카이트 파마 인코포레이티드 | 관리 연속성 및 신원 연속성 생물학적 샘플 추적으로 환자-특이적 면역요법 절차를 수행하기 위한 방법 및 시스템 |
| JP7404230B2 (ja) * | 2017-09-18 | 2023-12-25 | トラスティーズ オブ ボストン ユニバーシティ | ネトーシスおよび好中球活性化を処置するための方法 |
| KR102839644B1 (ko) * | 2017-09-22 | 2025-07-31 | 우시 바이올로직스 아일랜드 리미티드 | 신규한 이중특이적 폴리펩티드 복합체 |
| WO2019070755A1 (en) | 2017-10-02 | 2019-04-11 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER |
| WO2019084055A1 (en) | 2017-10-23 | 2019-05-02 | Massachusetts Institute Of Technology | CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS |
| WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
| WO2019094955A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas |
| CN109970864A (zh) * | 2017-12-28 | 2019-07-05 | 上海细胞治疗研究院 | 一种双向激活共刺激分子受体及其用途 |
| US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
| WO2019141774A1 (en) | 2018-01-19 | 2019-07-25 | Miltenyi Biotec Gmbh | Regulatory t cell expressing a chimeric antigen receptor |
| SG11202007755YA (en) | 2018-02-23 | 2020-09-29 | H Lee Moffitt Cancer Ct & Res | Cd83-binding chimeric antigen receptors |
| CA3092794A1 (en) | 2018-03-01 | 2019-09-06 | University Of Kansas | Techniques for generating cell-based therapeutics using recombinant t cell receptor genes |
| KR102867256B1 (ko) | 2018-03-15 | 2025-10-01 | 펀다멘탈 솔류션스 코포레이션 | 프로그램 가능한 면역세포 수용체 복합체 시스템 |
| US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
| WO2019222642A1 (en) * | 2018-05-18 | 2019-11-21 | Senti Biosciences, Inc. | Engineered immune cells and methods of use |
| US20210371932A1 (en) | 2018-06-01 | 2021-12-02 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
| US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| WO2020033273A1 (en) * | 2018-08-04 | 2020-02-13 | AbCyte Therapeutics Inc. | Multi-function and multi-targeting car system and methods for use thereof |
| WO2020033366A1 (en) | 2018-08-08 | 2020-02-13 | Nantbio, Inc. | Recombinant cd1-restricted t cells and methods |
| WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| US20210379057A1 (en) | 2018-10-16 | 2021-12-09 | Massachusetts Institute Of Technology | Nutlin-3a for use in treating a mycobacterium tuberculosis infection |
| WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| CN109722437B (zh) * | 2018-12-29 | 2020-01-07 | 广州百暨基因科技有限公司 | 一种通用型car-t细胞及其制备方法和用途 |
| CN111378622B (zh) * | 2018-12-29 | 2022-12-02 | 华东师范大学 | 核酸编码的car-t细胞及其制备方法和应用 |
| US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
| KR102746908B1 (ko) * | 2019-01-28 | 2024-12-26 | 우시 바이올로직스 아일랜드 리미티드 | 신규한 이중특이적 cd3/cd20 폴리펩티드 복합체 |
| WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
| EP3942023A1 (en) | 2019-03-18 | 2022-01-26 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
| CN114450013A (zh) * | 2019-04-12 | 2022-05-06 | 爱莫里大学 | 用于促进造血细胞的细胞毒性的组合物和方法 |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| US20220226464A1 (en) | 2019-05-28 | 2022-07-21 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
| WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
| US12421557B2 (en) | 2019-08-16 | 2025-09-23 | The Broad Institute, Inc. | Methods for predicting outcomes and treating colorectal cancer using a cell atlas |
| US12018081B1 (en) * | 2019-08-28 | 2024-06-25 | The Regents Of The University Of Colorado, A Body Corporate | Photoconjugation reactions for modification of specific proteins on live cells |
| US20220298501A1 (en) | 2019-08-30 | 2022-09-22 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
| CN114729059A (zh) * | 2019-09-11 | 2022-07-08 | 宾夕法尼亚大学董事会 | 包含前列腺干细胞抗原(psca)嵌合抗原受体(cars)的组合物和方法 |
| CN112500492B (zh) * | 2019-09-13 | 2023-08-04 | 中国科学院分子细胞科学卓越创新中心 | 一种嵌合抗原受体及其用途 |
| US12297426B2 (en) | 2019-10-01 | 2025-05-13 | The Broad Institute, Inc. | DNA damage response signature guided rational design of CRISPR-based systems and therapies |
| US12394502B2 (en) | 2019-10-02 | 2025-08-19 | The General Hospital Corporation | Method for predicting HLA-binding peptides using protein structural features |
| US12195725B2 (en) | 2019-10-03 | 2025-01-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity |
| US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
| US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
| US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
| US12165747B2 (en) | 2020-01-23 | 2024-12-10 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
| AU2021256053A1 (en) | 2020-04-17 | 2022-11-10 | City Of Hope | FLT3-targeted chimeric antigen receptor modified cells for treatment of FLT3-positive malignancies |
| CN111574616B (zh) * | 2020-06-17 | 2021-02-02 | 深圳豪石生物科技有限公司 | 分离的t细胞受体和应用 |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| WO2022111562A1 (zh) * | 2020-11-26 | 2022-06-02 | 上海医药集团生物治疗技术有限公司 | 一种经修饰的免疫细胞及其应用 |
| US20240112754A1 (en) * | 2021-03-12 | 2024-04-04 | Adaptive Biotechnologies Corporation | Crohn's Disease-Associated T Cell Receptor-Related Methods |
| CN116997654A (zh) | 2021-03-17 | 2023-11-03 | 第一三共株式会社 | 编码抗乙酰胆碱受体自身抗体的嵌合受体的基因 |
| CN115505572B (zh) * | 2021-06-22 | 2025-11-14 | 康立泰生物医药(青岛)有限公司 | 一种增强型抗肿瘤nk细胞及其制备方法和应用 |
| AU2023285071B2 (en) * | 2022-06-06 | 2025-02-20 | Caribou Biosciences, Inc. | Treatment of autoimmune diseases with engineered immune cells |
| CN116083369B (zh) * | 2022-09-01 | 2025-05-09 | 华中科技大学同济医学院附属同济医院 | 双特异性抗体修饰囊泡、双特异性抗体、核酸、重组载体、基因工程细胞、方法和应用 |
| WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
| WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
| WO2025059533A1 (en) | 2023-09-13 | 2025-03-20 | The Broad Institute, Inc. | Crispr enzymes and systems |
| WO2025064482A2 (en) * | 2023-09-19 | 2025-03-27 | Ginkgo Bioworks, Inc. | Chimeric immune cell receptors |
| CN117106035B (zh) * | 2023-10-25 | 2024-04-23 | 烟台药物研究所 | 一种肿瘤靶向多肽、多肽偶联药物及制备与应用 |
| WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
| WO2025117544A1 (en) | 2023-11-29 | 2025-06-05 | The Broad Institute, Inc. | Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA120409A (en) | 1909-05-13 | 1909-09-07 | Hiram Lucas Piper | Signal lamp |
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| US6080840A (en) | 1992-01-17 | 2000-06-27 | Slanetz; Alfred E. | Soluble T cell receptors |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5993434A (en) | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
| ATE183078T1 (de) | 1993-08-10 | 1999-08-15 | Gore & Ass | Zelleinkapselungsvorrichtung |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5626561A (en) | 1995-06-07 | 1997-05-06 | Gore Hybrid Technologies, Inc. | Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein |
| CA2190628C (en) | 1995-06-07 | 2000-05-30 | Mark D. Butler | An implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein |
| AU6854696A (en) | 1995-09-22 | 1997-04-09 | Gore Hybrid Technologies, Inc. | Improved cell encapsulation device |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| WO1998046645A2 (en) | 1997-04-14 | 1998-10-22 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | Method for the production of antihuman antigen receptors and uses thereof |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
| US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
| US6678556B1 (en) | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
| US7171264B1 (en) | 1999-05-10 | 2007-01-30 | Genetronics, Inc. | Intradermal delivery of active agents by needle-free injection and electroporation |
| ATE511400T1 (de) | 2000-03-03 | 2011-06-15 | Genetronics Inc | Nukleinsäure-fomulierungen zur genverabreichung |
| MXPA02010011A (es) | 2000-04-11 | 2003-04-25 | Genentech Inc | Anticuerpos multivalentes y usos para los mismos. |
| EP1188825A1 (en) * | 2000-09-18 | 2002-03-20 | Universiteit Leiden | T cell receptor transfer into a candidate effector cell or a precursor thereof |
| DE10109854A1 (de) * | 2001-03-01 | 2002-09-12 | Thomas Stanislawski | Polypeptide eines hdm2-Protein spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| CA2484182A1 (en) * | 2002-04-29 | 2003-11-13 | Genpat77 Pharmacogenetics Ag | Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis |
| US20040014645A1 (en) | 2002-05-28 | 2004-01-22 | Advisys, Inc. | Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system |
| US7446190B2 (en) * | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| US20050070841A1 (en) | 2002-07-04 | 2005-03-31 | Inovio As | Electroporation device and injection apparatus |
| DE10244457A1 (de) * | 2002-09-24 | 2004-04-01 | Johannes-Gutenberg-Universität Mainz | Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren |
| DK1641818T3 (da) | 2003-07-04 | 2009-03-16 | Affibody Ab | Polypeptider der har bindingsaffinitet for HER2 |
| DE05733048T1 (de) | 2004-04-06 | 2007-05-10 | Affibody Ab | Serumalbuminbindende peptidkonjugate zur arzneimittelherstellung |
| EP1611850A1 (fr) * | 2004-06-28 | 2006-01-04 | Cardio Life Research S.A. | Dispositif d'occlusion et de ponction étanche pour structure anatomique. |
| CN101072880A (zh) * | 2004-07-01 | 2007-11-14 | VIRxSYS股份有限公司 | 载体包装细胞系 |
| US7585960B2 (en) | 2005-05-11 | 2009-09-08 | Theramab Gmbh | Nucleic acids encoding superagonistic anti-CD28 antibodies |
| HRP20080053A2 (hr) | 2005-07-01 | 2009-08-31 | Medarex | Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1) |
| GB0524788D0 (en) | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
| WO2007120234A2 (en) | 2005-12-07 | 2007-10-25 | Genetronics, Inc | Variable volume electroporation chamber and methods therefore |
| EP2183275B1 (en) | 2007-08-03 | 2014-10-29 | Affibody AB | Igf-1r binding polypeptides and their use |
| EP2072525A1 (en) | 2007-12-21 | 2009-06-24 | Affibody AB | New polypeptides having affinity for HER2 |
| AU2009204501B2 (en) | 2008-01-07 | 2015-02-12 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
| MX2011004467A (es) * | 2008-10-31 | 2011-07-28 | Biogen Idec Inc | Moleculas de objetivo light y usos de las mismas. |
| JO3096B1 (ar) | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| GB0917090D0 (en) | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| EP2494038B1 (en) * | 2009-10-27 | 2019-06-26 | Immunicum AB | Method for proliferation of antigen-specific t cells |
| CN102812043A (zh) * | 2009-11-19 | 2012-12-05 | 新加坡国立大学 | 用于制备t细胞受体样单克隆抗体的方法及其用途 |
| WO2012040012A1 (en) * | 2010-09-21 | 2012-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-ssx-2 t cell receptors and related materials and methods of use |
| PE20141520A1 (es) * | 2011-07-29 | 2014-11-17 | Univ Pennsylvania | Receptores coestimuladores de cambio |
| JP5737082B2 (ja) | 2011-08-31 | 2015-06-17 | 富士通株式会社 | ポインタ位置補正方法、ポインタ位置補正プログラムおよびサーバ装置 |
| CA2848410A1 (en) * | 2011-09-16 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Rna engineered t cells for the treatment of cancer |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| CN104583230A (zh) * | 2012-07-13 | 2015-04-29 | 宾夕法尼亚大学董事会 | 通过共同引入双特异性抗体增强car t细胞的活性 |
| JP6441802B2 (ja) * | 2012-10-02 | 2018-12-19 | メモリアル スローン ケタリング キャンサー センター | 免疫療法のための組成物および方法 |
| KR102363191B1 (ko) * | 2013-02-26 | 2022-02-17 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
| CA2904230A1 (en) * | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Engager cells for immunotherapy |
| MA41538A (fr) * | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
-
2015
- 2015-10-30 JP JP2017523266A patent/JP7372728B2/ja active Active
- 2015-10-30 HK HK18102826.6A patent/HK1243333A1/zh unknown
- 2015-10-30 US US15/518,922 patent/US20170258835A1/en active Pending
- 2015-10-30 CN CN201580071613.7A patent/CN107106670A/zh active Pending
- 2015-10-30 EP EP15855013.7A patent/EP3212225B1/en active Active
- 2015-10-30 EP EP25207728.4A patent/EP4653013A2/en active Pending
- 2015-10-30 AU AU2015338984A patent/AU2015338984A1/en not_active Abandoned
- 2015-10-30 WO PCT/US2015/058339 patent/WO2016070061A1/en not_active Ceased
- 2015-10-30 CA CA2964958A patent/CA2964958A1/en not_active Abandoned
- 2015-10-30 KR KR1020177014658A patent/KR20170074243A/ko not_active Withdrawn
-
2021
- 2021-05-19 JP JP2021084334A patent/JP2021121208A/ja not_active Withdrawn
-
2023
- 2023-05-30 JP JP2023088510A patent/JP7757343B2/ja active Active
-
2025
- 2025-10-08 JP JP2025169833A patent/JP2025188145A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533706A5 (show.php) | ||
| JP2017535261A5 (show.php) | ||
| Liu et al. | Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T | |
| US20220347219A1 (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| JP7273421B2 (ja) | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 | |
| Zhang et al. | Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside | |
| JP2021058196A5 (show.php) | ||
| Rezvani et al. | Engineering natural killer cells for cancer immunotherapy | |
| Vitale et al. | An historical overview: the discovery of how NK cells can kill enemies, recruit defense troops, and more | |
| JP7146397B2 (ja) | 改変γδＴ細胞 | |
| Bollino et al. | Chimeric antigen receptor–engineered natural killer and natural killer T cells for cancer immunotherapy | |
| JP2017533707A5 (show.php) | ||
| Kriegsmann et al. | NKT cells—New players in CAR cell immunotherapy? | |
| Dianat‐Moghadam et al. | Natural killer cell–based immunotherapy: From transplantation toward targeting cancer stem cells | |
| JP2018504910A5 (show.php) | ||
| IL320642A (en) | Preparations and methods for engineering T cells | |
| CN105848484A (zh) | 用于免疫治疗的多克隆γδ T细胞 | |
| JP2017535292A5 (show.php) | ||
| CN110072533A (zh) | 选择性扩增γδT细胞群的方法及其组合物 | |
| JP2021525518A (ja) | 細胞をゲノム編集及び活性化するための方法 | |
| TWI899050B (zh) | 通用抗原呈現細胞及其用途 | |
| JP2014533928A5 (show.php) | ||
| US20160237407A1 (en) | Universal donor chimeric antigen receptor cells | |
| CA3189677A1 (en) | Chimeric molecules providing targeted costimulation for adoptive cell therapy | |
| CN115916963A (zh) | 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途 |